Macrogol Stada (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol Stada is an oral osmotic laxative used to manage conditions related to impaired bowel motility and to prepare the colon for diagnostic procedures.

• Chronic constipation: provides gentle, water‑based stool softening to facilitate regular bowel movements.
• Occasional constipation: offers rapid relief of infrequent constipation episodes.
• Bowel preparation for colonoscopy: clears the intestinal tract to improve visualization during endoscopic examinations.
• Post‑operative ileus prevention: helps restore normal bowel function in patients after abdominal surgery.

• Macrogol 3350 (polyethylene glycol 3350) is a high‑molecular‑weight polymer that is poorly absorbed from the gastrointestinal tract. It binds water molecules through hydrogen bonding, creating an osmotic gradient that retains water in the intestinal lumen. The increased intraluminal fluid softens stool, expands the stool volume, and stimulates peristalsis, thereby promoting bowel evacuation while the accompanying electrolytes help maintain fluid balance.

Macrogol Stada may cause a range of adverse reactions, most of which are related to its osmotic activity in the gastrointestinal tract.

Common Side Effects

• Abdominal bloating: sensation of fullness or swelling in the abdomen.
• Nausea: mild to moderate feeling of queasiness.
• Flatulence: increased intestinal gas.
• Diarrhea: loose, watery stools occurring more frequently.
• Abdominal cramps: intermittent painful contractions of the gut.
• Headache: mild to moderate head discomfort.

Serious or Rare Side Effects

• Severe electrolyte imbalance: abnormal levels of sodium, potassium or chloride that may require medical attention.
• Dehydration: excessive loss of body fluids leading to dizziness or low blood pressure.
• Allergic reaction: rash, itching, swelling or difficulty breathing.
• Persistent abdominal pain or rectal bleeding: may indicate underlying gastrointestinal injury.

When prescribing Macrogol Stada, clinicians should consider patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust use as reduced clearance may affect electrolyte balance.
• Heart failure: avoid excessive fluid shifts that could exacerbate cardiac load.
• Electrolyte disorders: monitor serum sodium and potassium levels during therapy.
• Bowel obstruction or inflammatory bowel disease: contraindicated due to risk of worsening obstruction.
• Pediatric and elderly patients: start with lower doses and observe tolerance.
• Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Macrogol Stada can interact with other medications, altering their absorption or electrolyte status.

Major Interactions (Avoid)

• Concurrent use of other osmotic laxatives: may cause severe diarrhea and electrolyte loss.
• High‑dose electrolyte solutions: risk of additive electrolyte disturbances.
• Digoxin: altered absorption may affect serum levels.

Moderate Interactions (Monitor Closely)

• Antacids: may reduce the efficacy of macrogol by changing gastric pH.
• Diuretics: combined effect on fluid and electrolyte balance requires monitoring.
• NSAIDs: increased risk of gastrointestinal irritation.
• Warfarin: potential alteration in absorption could affect anticoagulation control.